HDL-Cholesterol Predicts Survival in Cirrhotic Patients with Gastrointestinal Bleeding
|
By LabMedica International staff writers Posted on 10 Dec 2020 |

Image: Histopathology of a cirrhotic liver. High-density lipoprotein cholesterol predicts survival in cirrhotic patients with acute gastrointestinal bleeding (Photo courtesy of Loyola University Chicago).
Liver cirrhosis is an important cause of morbidity and mortality as a consequence of continuous liver injuries. Acute gastrointestinal bleeding is a serious complication and critical clinical event in cirrhotic patients. Hepatitis B virus (HBV) is the leading cause of liver cirrhosis in China.
Since the liver plays a crucial role in cholesterol homeostasis, hypercholesterolemia often occurs in patients with chronic liver diseases. The decrease in serum levels of lipids and lipoproteins is highly prevalent in cirrhotic patients, with a prevalence that increases in parallel with the disease severity.
Infectious disease specialists at the Peking University First Hospital (Beijing, China) evaluated from January 2008 to December 2015, consecutive cirrhotic patients with acute gastrointestinal bleeding who were randomly divided into the derivation (n = 629) and validation (n = 314) cohorts. Liver cirrhosis was confirmed either by liver biopsy or by clinical presentations, routine liver function tests and medical imaging techniques. A logistic regression model was established to confirm the association between lipoprotein cholesterol and mortality. Routine biochemical tests were performed in the hospital laboratory. Lipid profiles include triglyceride, cholesterol, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C).
The investigators reported that on ROC analysis, HDL-C showed excellent diagnostic accuracy for six-week mortality, with an area under the receiver operating characteristic curves (AUROC) of 0.847 (95% CI 0.789–0.905). The best cut-off value of HDL-C was 0.54 mmol/L, with a sensitivity of 85.1% and specificity of 74.2%. The laboratory variables significantly associated with 6-week mortality in the univariate analysis were as follows: hepatocellular carcinoma (HCC), packed red blood cells (PRBC) transfusion, hemoglobin (HGB), total leukocyte count (WBC), alanine aminotransferase (ALT), serum sodium (Na), total bilirubin (TBIL), albumin (ALB), cholesterol, HDL-C, LDL-C, serum creatinine (Scr), international normalized ratio (INR), fibrinogen (FIB). Multivariate logistic regression analyses showed that TBIL, HDL-C, Na, and HGB were independently associated with six-week mortality.
The authors concluded that HDL-C is a potential indicator for the prognosis of patients with cirrhosis and acute gastrointestinal bleeding. The new algorithm based on HDL-C allowed an accurate predictive assessment of 6-week mortality after bleeding attack. The study was published on November 16, 2020 in the journal BMC Gastroenterology.
Related Links:
Peking University First Hospital
Since the liver plays a crucial role in cholesterol homeostasis, hypercholesterolemia often occurs in patients with chronic liver diseases. The decrease in serum levels of lipids and lipoproteins is highly prevalent in cirrhotic patients, with a prevalence that increases in parallel with the disease severity.
Infectious disease specialists at the Peking University First Hospital (Beijing, China) evaluated from January 2008 to December 2015, consecutive cirrhotic patients with acute gastrointestinal bleeding who were randomly divided into the derivation (n = 629) and validation (n = 314) cohorts. Liver cirrhosis was confirmed either by liver biopsy or by clinical presentations, routine liver function tests and medical imaging techniques. A logistic regression model was established to confirm the association between lipoprotein cholesterol and mortality. Routine biochemical tests were performed in the hospital laboratory. Lipid profiles include triglyceride, cholesterol, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C).
The investigators reported that on ROC analysis, HDL-C showed excellent diagnostic accuracy for six-week mortality, with an area under the receiver operating characteristic curves (AUROC) of 0.847 (95% CI 0.789–0.905). The best cut-off value of HDL-C was 0.54 mmol/L, with a sensitivity of 85.1% and specificity of 74.2%. The laboratory variables significantly associated with 6-week mortality in the univariate analysis were as follows: hepatocellular carcinoma (HCC), packed red blood cells (PRBC) transfusion, hemoglobin (HGB), total leukocyte count (WBC), alanine aminotransferase (ALT), serum sodium (Na), total bilirubin (TBIL), albumin (ALB), cholesterol, HDL-C, LDL-C, serum creatinine (Scr), international normalized ratio (INR), fibrinogen (FIB). Multivariate logistic regression analyses showed that TBIL, HDL-C, Na, and HGB were independently associated with six-week mortality.
The authors concluded that HDL-C is a potential indicator for the prognosis of patients with cirrhosis and acute gastrointestinal bleeding. The new algorithm based on HDL-C allowed an accurate predictive assessment of 6-week mortality after bleeding attack. The study was published on November 16, 2020 in the journal BMC Gastroenterology.
Related Links:
Peking University First Hospital
Latest Clinical Chem. News
- Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
- Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
- Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
- Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
- Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
- Blood Protein Panel Predicts Timing of ALS Symptom Onset
- Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
- Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
- New Machine-Learning Equation Improves LDL Cholesterol Assessment
- Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
- Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
- Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
- New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
- Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
- Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
- Alzheimer’s Biomarkers Identify Faster Cognitive Decline in Adults Over 80
Channels
Molecular Diagnostics
view channel
New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance
Cyclospora cayetanensis, a food- and waterborne intestinal parasite, can cause prolonged diarrhea, fatigue, and abdominal cramping, placing added strain on urgent care and emergency departments during outbreaks.... Read more
Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer
Assessing early benefit from immunotherapy in advanced non-small cell lung cancer can be challenging because radiographic responses may take months to become clear. Early scans can also be difficult to... Read moreHematology
view channel
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read moreProteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







